Erasca, Inc. (ERAS) 10-Year Financial Performance & Capital Metrics

ERAS • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutErasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.Show more

Revenue $0
EBITDA -$176M -27.6%
Net Income -$162M -29.3%
EPS (Diluted) -0.69 +16.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -43.68% -27.2%
ROIC -39.2% +14.6%
Debt/Equity 0.12 -30.5%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 97 (top 3%)
✓Trading near 52-week high

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 55.7% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM19.75%

EPS CAGR

10Y-

5Y-

3Y-

TTM45.78%

ROCE

10Y Avg-55.05%

5Y Avg-61.02%

3Y Avg-43.07%

Latest-42.74%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	0	0	829K	2.64M	3.73M	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	0	0	-829K	-2.64M	-3.73M	0
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-2.19%	-0.41%	1%
Operating Expenses+	13.29M	109.25M	124.05M	244.81M	137.79M	179.59M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	3.68M	7.96M	22.62M	32.99M	37.7M	41.73M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	9.62M	101.3M	73.92M	112.46M	103.82M	115.36M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	0	27.52M	99.36M	-3.73M	22.5M
Operating Income+	-13.29M	-109.25M	-124.88M	-247.45M	-141.53M	-179.59M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	-7.22%	-0.14%	-0.98%	0.43%	-0.27%
EBITDA+	-12.98M	-108.71M	-124.05M	-244.81M	-137.79M	-175.78M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	-7.37%	-0.14%	-0.97%	0.44%	-0.28%
D&A (Non-Cash Add-back)	310K	540K	829K	2.64M	3.73M	3.81M
EBIT	-13.29M	-37.51M	-122.76M	-242.81M	-125.04M	-157.09M
Net Interest Income+	1.3M	336K	190K	-196.46M	16.71M	20.09M
Interest Income	1.3M	336K	190K	4.9M	16.71M	20.09M
Interest Expense	0	0	0	201.36M	0	0
Other Income/Expense	1.25M	7.59M	2.12M	4.64M	16.48M	17.94M
Pretax Income+	-12.04M	-101.66M	-122.76M	-242.81M	-125.04M	-161.65M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-12.04M	-101.66M	-122.76M	-242.81M	-125.04M	-161.65M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	-7.44%	-0.21%	-0.98%	0.49%	-0.29%
Net Income (Continuing)	-12.04M	-101.66M	-122.76M	-242.81M	-125.04M	-161.65M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.10	-0.85	-1.03	-1.99	-0.83	-0.69
EPS Growth %	-	-7.5%	-0.21%	-0.93%	0.58%	0.17%
EPS (Basic)	-0.10	-0.85	-1.03	-1.99	-0.83	-0.69
Diluted Shares Outstanding	118.96M	118.96M	119.1M	122.02M	150.18M	233.82M
Basic Shares Outstanding	118.96M	118.96M	119.1M	122.02M	150.18M	233.82M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	51.12M	119.99M	420.02M	444.5M	320.68M	308.79M
Cash & Short-Term Investments	50.37M	118.7M	414.48M	435.62M	312.35M	298.31M
Cash Only	29.58M	65.38M	360.49M	284.22M	93.08M	67.74M
Short-Term Investments	20.79M	53.33M	53.99M	151.4M	219.28M	230.57M
Accounts Receivable	0	0	0	0	0	2.3M
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	1.29M	100K	748K	1.1M	8.18M
Total Non-Current Assets+	4.39M	4.83M	81.4M	70.41M	74.62M	193.73M
Property, Plant & Equipment	4.33M	4.07M	33.31M	65.23M	60.19M	48.54M
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	312K	44.77M	2M	10.05M	142.16M
Other Non-Current Assets	56K	451K	3.32M	3.18M	4.38M	3.03M
Total Assets+	55.51M	124.83M	501.42M	514.91M	395.3M	502.53M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	1.25%	3.02%	0.03%	-0.23%	0.27%
Total Current Liabilities+	2.75M	13.68M	26.22M	48.69M	26.16M	31.39M
Accounts Payable	1.38M	878K	4.68M	23.05M	2M	468K
Days Payables Outstanding	-	-	2.06K	3.19K	195.61	-
Short-Term Debt	0	877K	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	447K	9.51M	4.16M	2.33M	10.78M	0
Current Ratio	18.59x	8.77x	16.02x	9.13x	12.26x	9.84x
Quick Ratio	18.59x	8.77x	16.02x	9.13x	12.26x	9.84x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	66.37M	3.72M	18.66M	54.37M	52.45M	47.63M
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	2.96M	2.11M	18.51M	53.79M	51.89M	47.27M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	63.4M	1.61M	158K	573K	566K	362K
Total Liabilities	69.12M	17.4M	44.89M	103.06M	78.61M	79.03M
Total Debt+	3.69M	2.99M	18.79M	55.1M	55.86M	51.89M
Net Debt	-25.89M	-62.39M	-341.7M	-229.12M	-37.22M	-15.85M
Debt / Equity	-	0.03x	0.04x	0.13x	0.18x	0.12x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-	-	-1.23x	-	-
Total Equity+	-13.6M	107.42M	456.53M	411.85M	316.69M	423.5M
Equity Growth %	-	8.9%	3.25%	-0.1%	-0.23%	0.34%
Book Value per Share	-0.11	0.90	3.83	3.38	2.11	1.81
Total Shareholders' Equity	-13.6M	107.42M	456.53M	411.85M	316.69M	423.5M
Common Stock	3K	3K	12K	15K	15K	28K
Retained Earnings	-13.74M	-115.4M	-238.17M	-480.97M	-606.01M	-767.66M
Treasury Stock	-124K	0	0	0	0	0
Accumulated OCI	11K	2K	-162K	-1.04M	77K	405K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-10.38M	-32.69M	-79.6M	-103.26M	-101.22M	-109.42M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	-2.15%	-1.44%	-0.3%	0.02%	-0.08%
Net Income	-12.04M	-101.66M	-122.76M	-242.81M	-125.04M	-161.65M
Depreciation & Amortization	310K	540K	829K	2.64M	3.73M	3.81M
Stock-Based Compensation	122K	797K	8.33M	20.11M	26.23M	26.97M
Deferred Taxes	0	0	-1.51M	0	0	0
Other Non-Cash Items	-483K	64.35M	27.81M	101.01M	-6.95M	19.72M
Working Capital Changes	1.71M	3.29M	7.71M	15.79M	813K	1.74M
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	1.17M	-380K	1.34M	676K	-886K	-1.53M
Cash from Investing+	-20.89M	-71.2M	-64.59M	-71.08M	-91.22M	-156.62M
Capital Expenditures	-597K	-947K	-18.89M	-16.55M	-1.77M	-60K
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	-37.74M	-7.68M	-4M	-20M	-22.5M
Cash from Financing+	16.86M	139.99M	439.4M	98.08M	1.29M	240.7M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	3.02M	3M	2.82M	0	1.64M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-10.97M	-71.38M	-98.48M	-119.81M	-102.99M	-131.98M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	-5.5%	-0.38%	-0.22%	0.14%	-0.28%
FCF per Share	-0.09	-0.60	-0.83	-0.98	-0.69	-0.56
FCF Conversion (FCF/Net Income)	0.86x	0.32x	0.65x	0.43x	0.81x	0.68x
Interest Paid	0	0	0	0	0	0
Taxes Paid	13K	69K	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-216.72%	-43.54%	-55.92%	-34.33%	-43.68%
Return on Invested Capital (ROIC)	-	-2961.83%	-117.18%	-124.74%	-45.93%	-39.2%
Debt / Equity	-	0.03x	0.04x	0.13x	0.18x	0.12x
Interest Coverage	-	-	-	-1.23x	-	-
FCF Conversion	0.86x	0.32x	0.65x	0.43x	0.81x	0.68x

Frequently Asked Questions

Growth & Financials

Erasca, Inc. (ERAS) grew revenue by 0.0% over the past year. Growth has been modest.

Erasca, Inc. (ERAS) reported a net loss of $127.7M for fiscal year 2024.

Dividend & Returns

Erasca, Inc. (ERAS) has a return on equity (ROE) of -43.7%. Negative ROE indicates the company is unprofitable.

Erasca, Inc. (ERAS) had negative free cash flow of $98.4M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener